Today: 8 June 2026
Diageo share price today: DGE stock nudges up as investors line up for Feb. 25 results
3 February 2026
1 min read

Diageo share price today: DGE stock nudges up as investors line up for Feb. 25 results

London, February 3, 2026, 09:18 GMT — Regular session

  • Diageo shares edged up in early London trading, clawing back a fraction of Monday’s losses.
  • Investors are zeroing in on the upcoming results, spurred by a routine share-capital update and new broker commentary.
  • Investors will be eyeing the Feb. 25 interim reports closely for signs on demand, pricing, and cash flow.

Diageo shares edged up 0.36% to 1,675.5 pence by 0918 GMT, gaining 6 pence from Monday’s close of 1,669.5 pence. The price fluctuated between 1,673 and 1,689 pence.

That modest shift counts, as the next key date looms. Diageo plans to release interim results on Feb. 25, kicking off with a webcast at 0705 UK time featuring Sir Dave Lewis and Nik Jhangiani. A Q&A session follows at 0930.

Investors are looking for clear signals on whether demand is stabilizing in the U.S. and China after Diageo cut its outlook in November, citing softer conditions in both markets. “There is a plan in place… but whether a new CEO has a different strategy, no one will know,” said Richard Scrope, manager of the VT Tyndall Global Select Fund. Reuters

On Monday, the company released its latest “total voting rights” figure, a standard update shareholders use to check if they need to report stake changes under Financial Conduct Authority rules. Issued share capital was 2,432,425,480 ordinary shares as of Jan. 31, with 205,986,795 held in treasury, leaving total voting rights at 2,226,438,685. The London Stock Exchange’s RNS service carried the announcement. Investegate

Broker buzz remains alive. RBC Capital Markets stuck to its “outperform” rating, setting a 2,000 pence price target, MarketBeat noted. MarketBeat

The backdrop is still challenging. In its fiscal first-quarter trading update last November, Diageo reported flat organic net sales, with volume gains offset by negative price and mix effects. Reported net sales declined 2.2% to $4.9 billion, dragged down by disposals. The company pointed to adverse mix in Asia Pacific, noting weaker performance in China’s “Chinese white spirits.” www.diageo.com

Traders are keeping an eye on the interim figures to see if changes in mix and pricing emerge, along with any improvement in cash flow that might relieve debt and funding strains.

The risk is straightforward: if consumers continue trading down or discounts climb, margins could slide again, pushing another guidance reset back into play.

Feb. 25 is the real trigger here — it’s not just about the headline figures. Investors will be watching closely for any clues on demand trends in crucial markets, as well as management’s take on how they plan to juggle investment, dividends, and fixing the balance sheet.

Stock Market Today

  • Goldman Sachs Revises Forecast, Sees No Fed Rate Cuts in 2024
    June 8, 2026, 4:45 AM EDT. Goldman Sachs economists have revised their forecast, now expecting no interest rate cuts from the Federal Reserve in 2024. The change is driven by a stronger-than-expected labor market, which reduces the likelihood of the Fed easing policy this year. This signals continued monetary tightening amid persistent economic resilience, affecting market expectations for borrowing costs and investment decisions.

Latest articles

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

SpaceX Sets IPO at $135, Retail Buzz Ahead of SPCX Nasdaq Debut

8 June 2026
SpaceX’s $75 billion IPO launches June 12 at $135 a share, with retail demand already double the shares on offer and 30% of the deal earmarked for individuals, but 2025 losses of $4.94 billion and a $1.75 trillion target valuation raise questions about post-IPO pricing as index entry and profitability remain uncertain.
Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

Eli Lilly Set for Key Monday After New Weight-Loss Drug Data

8 June 2026
Eli Lilly closed at $1,131.42, up 0.55%, after releasing late-stage data showing its obesity drug retatrutide led to 28.3% weight loss over 80 weeks and reduced sleep apnea and knee pain, fueling hopes its obesity pipeline could expand beyond weight loss as rivals Boehringer Ingelheim and Zealand Pharma unveiled competing data, setting up a key test for Lilly’s trillion-dollar valuation as trading resumes.
SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

SK Hynix Slips Even After Nvidia Deal as Korean AI Shares Slide

8 June 2026
SK Hynix plunged 7.68% to 1,911,000 won despite sealing a multi-year Nvidia memory deal, as fears of a U.S. rate hike and a tech stock rout triggered circuit breakers and an 8.3% KOSPI crash, overshadowing strong AI demand and ongoing HBM supply constraints.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 08.06.2026

8 June 2026
LIVEMarkets rolling coverageStarted: June 8, 2026, 4:00 AM EDTUpdated: June 8, 2026, 4:47 AM EDT Goldman Sachs Revises Forecast, Sees No Fed Rate Cuts in 2024 June 8, 2026, 4:45 AM EDT. Goldman Sachs economists have revised their forecast, now expecting no interest rate cuts from the Federal Reserve in 2024. The change is driven by a stronger-than-expected labor market, which reduces the likelihood of the Fed easing policy this year. This signals continued monetary tightening amid persistent economic resilience, affecting market expectations for borrowing costs and investment decisions. Goldman Sachs No Longer Expects Fed Intere… Oil Prices Surge Following
Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom
Previous Story

Nebius (NBIS) stock rebounds after a wild session as Feb. 12 results loom

Legal & General share price rises after Meiji Yasuda deal closes, £1.2bn buyback in focus
Next Story

Legal & General share price rises after Meiji Yasuda deal closes, £1.2bn buyback in focus

Go toTop